Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach

Wenxiang Bai,1,2,* Honghua Wang,1,* Hua Bai1,3 1Comprehensive Cancer Center, Xiangshui People’s Hospital, Xiangshui 224600, People’s Republic of China; 2Department of Respiratory Medicine, Xiangshui People’s Hospital, Xiangshui, 224600, People’s Republic of Ch...

Full description

Bibliographic Details
Main Authors: Bai W, Wang H, Bai H
Format: Article
Language:English
Published: Dove Medical Press 2020-01-01
Series:Pharmacogenomics and Personalized Medicine
Subjects:
Online Access:https://www.dovepress.com/identification-of-candidate-genes-and-therapeutic-agents-for-light-cha-peer-reviewed-article-PGPM
_version_ 1818035566436941824
author Bai W
Wang H
Bai H
author_facet Bai W
Wang H
Bai H
author_sort Bai W
collection DOAJ
description Wenxiang Bai,1,2,* Honghua Wang,1,* Hua Bai1,3 1Comprehensive Cancer Center, Xiangshui People’s Hospital, Xiangshui 224600, People’s Republic of China; 2Department of Respiratory Medicine, Xiangshui People’s Hospital, Xiangshui, 224600, People’s Republic of China; 3Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hua BaiComprehensive Cancer Center, Xiangshui People’s Hospital, Xiangshui 224600, People’s Republic of ChinaEmail baihua92@126.comObjective: Systemic amyloid light chain (AL) amyloidosis is a rare plasma cell disease. However, the regulatory mechanisms of AL amyloidosis have not been thoroughly uncovered, identification of candidate genes and therapeutic agents for this disease is crucial to provide novel insights into exploring the regulatory mechanisms underlying AL amyloidosis.Methods: The gene expression profile of GSE73040, including 9 specimens from AL amyloidosis patients and 5 specimens from normal control, was downloaded from GEO datasets. Differentially expressed genes (DEGs) were sorted with regard to AL amyloidosis versus normal control group using Limma package. The gene enrichment analyses including GO and KEGG pathway were performed using DAVID website subsequently. Furthermore, the protein–protein interaction (PPI) network for DEGs was constructed by Cytoscape software and STRING database. DEGs were mapped to the connectivity map datasets to identify potential molecular agents of AL amyloidosis.Results: A total of 1464 DEGs (727 up-regulated, 737 down-regulated) were identified in AL amyloidosis samples versus control samples, these dysregulated genes were associated with the dysfunction of ribosome biogenesis and immune response. PPI network and module analysis uncovered that several crucial genes were defined as candidate genes, including ITGAM, ITGB2, ITGAX, IMP3 and FBL. More importantly, we identified the small molecular agents (AT-9283, Ritonavir and PKC beta-inhibitor) as the potential drugs for AL amyloidosis.Conclusion: Using bioinformatics approach, we have identified candidate genes and pathways in AL amyloidosis, which can extend our understanding of the cause and molecular mechanisms, and these crucial genes and pathways could act as biomarkers and therapeutic targets for AL amyloidosis.Keywords: light chain amyloidosis, bioinformatics approach, differentially expressed genes, candidate genes, therapeutic agent
first_indexed 2024-12-10T06:57:06Z
format Article
id doaj.art-f8c3e10813d441b5ad0e98f4fd6891c6
institution Directory Open Access Journal
issn 1178-7066
language English
last_indexed 2024-12-10T06:57:06Z
publishDate 2020-01-01
publisher Dove Medical Press
record_format Article
series Pharmacogenomics and Personalized Medicine
spelling doaj.art-f8c3e10813d441b5ad0e98f4fd6891c62022-12-22T01:58:25ZengDove Medical PressPharmacogenomics and Personalized Medicine1178-70662020-01-01Volume 1238739650825Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics ApproachBai WWang HBai HWenxiang Bai,1,2,* Honghua Wang,1,* Hua Bai1,3 1Comprehensive Cancer Center, Xiangshui People’s Hospital, Xiangshui 224600, People’s Republic of China; 2Department of Respiratory Medicine, Xiangshui People’s Hospital, Xiangshui, 224600, People’s Republic of China; 3Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hua BaiComprehensive Cancer Center, Xiangshui People’s Hospital, Xiangshui 224600, People’s Republic of ChinaEmail baihua92@126.comObjective: Systemic amyloid light chain (AL) amyloidosis is a rare plasma cell disease. However, the regulatory mechanisms of AL amyloidosis have not been thoroughly uncovered, identification of candidate genes and therapeutic agents for this disease is crucial to provide novel insights into exploring the regulatory mechanisms underlying AL amyloidosis.Methods: The gene expression profile of GSE73040, including 9 specimens from AL amyloidosis patients and 5 specimens from normal control, was downloaded from GEO datasets. Differentially expressed genes (DEGs) were sorted with regard to AL amyloidosis versus normal control group using Limma package. The gene enrichment analyses including GO and KEGG pathway were performed using DAVID website subsequently. Furthermore, the protein–protein interaction (PPI) network for DEGs was constructed by Cytoscape software and STRING database. DEGs were mapped to the connectivity map datasets to identify potential molecular agents of AL amyloidosis.Results: A total of 1464 DEGs (727 up-regulated, 737 down-regulated) were identified in AL amyloidosis samples versus control samples, these dysregulated genes were associated with the dysfunction of ribosome biogenesis and immune response. PPI network and module analysis uncovered that several crucial genes were defined as candidate genes, including ITGAM, ITGB2, ITGAX, IMP3 and FBL. More importantly, we identified the small molecular agents (AT-9283, Ritonavir and PKC beta-inhibitor) as the potential drugs for AL amyloidosis.Conclusion: Using bioinformatics approach, we have identified candidate genes and pathways in AL amyloidosis, which can extend our understanding of the cause and molecular mechanisms, and these crucial genes and pathways could act as biomarkers and therapeutic targets for AL amyloidosis.Keywords: light chain amyloidosis, bioinformatics approach, differentially expressed genes, candidate genes, therapeutic agenthttps://www.dovepress.com/identification-of-candidate-genes-and-therapeutic-agents-for-light-cha-peer-reviewed-article-PGPMlight chain amyloidosisbioinformatics approachdifferentially expressed genescandidate genestherapeutic agent
spellingShingle Bai W
Wang H
Bai H
Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach
Pharmacogenomics and Personalized Medicine
light chain amyloidosis
bioinformatics approach
differentially expressed genes
candidate genes
therapeutic agent
title Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach
title_full Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach
title_fullStr Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach
title_full_unstemmed Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach
title_short Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach
title_sort identification of candidate genes and therapeutic agents for light chain amyloidosis based on bioinformatics approach
topic light chain amyloidosis
bioinformatics approach
differentially expressed genes
candidate genes
therapeutic agent
url https://www.dovepress.com/identification-of-candidate-genes-and-therapeutic-agents-for-light-cha-peer-reviewed-article-PGPM
work_keys_str_mv AT baiw identificationofcandidategenesandtherapeuticagentsforlightchainamyloidosisbasedonbioinformaticsapproach
AT wangh identificationofcandidategenesandtherapeuticagentsforlightchainamyloidosisbasedonbioinformaticsapproach
AT baih identificationofcandidategenesandtherapeuticagentsforlightchainamyloidosisbasedonbioinformaticsapproach